Regeneron Pharmaceuticals
REGN
1,192 hedge funds and large institutions have $76.1B invested in Regeneron Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 131 funds opening new positions, 441 increasing their positions, 422 reducing their positions, and 83 closing their positions.
58% more first-time investments, than exits
New positions opened: 131 | Existing positions closed: 83
40% more funds holding in top 10
Funds holding in top 10: 30 → 42 (+12)
14% more capital invested
Capital invested by funds: $66.7B → $76.1B (+$9.37B)
4.18% more ownership
Funds ownership: 88.01% → 92.19% (+4.2%)
3% more funds holding
Funds holding: 1,159 → 1,192 (+33)
5% more repeat investments, than reductions
Existing positions increased: 441 | Existing positions reduced: 422
8% less call options, than puts
Call options by funds: $1.93B | Put options by funds: $2.09B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWA
EP Wealth Advisors
Torrance,
California
|
+$3.43B |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$1.39B |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$470M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$343M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$318M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.25B |
| 2 |
WHG
Westwood Holdings Group
Dallas,
Texas
|
-$1.12B |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$489M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$311M |
| 5 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$201M |
REGN Hedge Fund Activity: Q1 2023 in Review
1,192 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2023, worth a combined $76.1B — up 14% from $66.7B a quarter earlier.
Buyers outnumbered sellers: 131 funds opened new REGN positions and 83 closed out — a net gain of 48 holders — while 441 added to existing stakes and 422 trimmed.
The largest buyer was EP Wealth Advisors, adding an estimated $3.43B. The largest seller was Fidelity Investments, cutting an estimated $1.25B.
- 1,192 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2023, up from 1,159 in Q4 2022.
- Funds reported $76.1B of Regeneron Pharmaceuticals stock for Q1 2023, up 14% quarter-over-quarter.
- 131 funds opened new Regeneron Pharmaceuticals positions in Q1 2023 and 83 closed out, a net change of +48 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2023 was EP Wealth Advisors, an estimated $3.43B added.
- The largest Regeneron Pharmaceuticals seller in Q1 2023 was Fidelity Investments, an estimated $1.25B sold.
Based on aggregated 13F filings for Q1 2023.